Insulin tregopil

Drug Profile

Insulin tregopil

Alternative Names: 843362; GW 843362; Hexyl Insulin M2; hexyl insulin monoconjugate 2; HIM2; IN-105; Insulin oral - Biocon; NIN 058

Latest Information Update: 30 Apr 2015

Price : $50

At a glance

  • Originator Nobex Corporation
  • Developer Biocon; Bristol-Myers Squibb
  • Class Antihyperglycaemics; Hormones; Insulins; Peptides
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Type 2 diabetes mellitus
  • Phase II Type 1 diabetes mellitus

Most Recent Events

  • 31 Dec 2014 Phase-Ib/IIa trials in Type-2 diabetes mellitus and Type-1 diabetes mellitus in USA (PO)
  • 24 Jul 2014 Insulin oral - Biocon is still in active development in India
  • 16 Nov 2012 Bristol Myer-Squibb enter a licensing option agreement with Biocon for insulin tregopil worldwide (excluding India)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top